



| REF |  |  | SYSTEM |
|-------------|---|---|----------------------------|
| 09015272190 | 09015272500 | 300 | cobas e 402 cobas e 801 |

English

System information

| Short name | ACN (application code number) |
|------------|-------------------------------|
| HTLV | 10219 |

Intended use

Immunoassay for the in vitro qualitative determination of antibodies to HTLV-I/II in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Regulatory approval

This assay has been CE marked according to Directive 98/79/EC. Test performance has been established and certified by a Notified Body according to the Common Technical Specifications (CTS) for diagnostic use and for screening of blood donations.

Summary

Human T-lymphotropic virus (HTLV) type I and II are two closely related retroviruses with 70 % nucleotide sequence homology.² HTLV-I comprises the different subtypes A-F. The geographic areas of the highest prevalence are Japan, Africa, the Caribbean islands and South America. Additional endemic regions include the Middle East and the Melanesian islands including Papua New Guinea.^{3,4} HTLV-II comprises two main subtypes, A and B.⁵ Both are present in intravenous drug users in North America, Europe, and Asia and have been found sporadically in Africa. HTLV-IIA is present in certain American Indian tribes of North, Central, and South America, including the Navajo and Pueblo in New Mexico and the Kayapo, Krahô, and Kaxuyana in Brazil.^{6,7}

HTLV is transmitted from mother-to-child, between intravenous drug users by needle sharing, by hetero- or homosexual intercourse and contaminated blood products.²

With a frequency of 15-30 %, mother-to-child transmission has a similar frequency as that of an untreated HIV-1 infection, and occurs predominantly in the postnatal period through breastfeeding.⁸

Transmission by blood products is strictly cell-associated; the virus is not transmitted by plasma or plasma-derived products.⁹ Recipients of contaminated blood seroconvert with a 40-60 % probability and an estimated seroconversion time of 51 days.⁴ The majority of HTLV-I infected individuals remain lifelong asymptomatic carriers. Only 2-3 % of the HTLV-I infected individuals develop adult T-cell leukemia (ATL) and 0.25-4 % develop HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).¹⁰ Although less than 10 % of HTLV-I carriers progress to ATL or HAM/TSP, the diseases are generally severe and progressively incapacitating. The disease type correlates with the route of infection; breastfeeding has been associated with ATL, and HAM/TSP with blood transfusion.² There have been some reports describing a correlation between HTLV-II infection and different diseases^{11,12} nevertheless the evidence is not nearly as clear as that for HTLV-I.

The Elecsys HTLV-I/II assay is used for screening of blood donors to ensure the safety of blood products and for diagnosis of HTLV infection.

Test principle

Double antigen sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 18 µL of sample, biotinylated HTLV-specific recombinant antigens (HTLV-I gp21 and HTLV-II p24) and HTLV-specific recombinant antigens (HTLV-I gp21 and HTLV-II p24) labeled with a ruthenium complex^{a)} react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined automatically by the software by comparing the electrochemiluminescence signal obtained from the reaction product of the sample with the signal of the cutoff value previously obtained by calibration.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The cobas e pack (M, R1, R2) is labeled as HTLV.

- M Streptavidin-coated microparticles, 1 bottle, 14.1 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 HTLV-specific recombinant antigens (E. coli)-biotin, 1 bottle, 16.7 mL:
Biotinylated HTLV-specific recombinant antigens (E. coli) > 0.3 mg/L; MES^{b)} buffer 50 mmol/L, pH 6.2; preservative.
- R2 HTLV-specific recombinant antigens (E. coli)~Ru(bpy)₃²⁺, 1 bottle, 16.7 mL:
HTLV-specific recombinant antigens (E. coli) labeled with ruthenium complex > 0.3 mg/L; MES buffer 50 mmol/L, pH 6.2; preservative.

b) MES = 2-morpholino-ethane sulfonic acid

- HTLV Cal1 Negative calibrator 1 (lyophilized), 1 bottle for 1.0 mL:
Human serum, non-reactive for anti-HTLV antibodies.
- HTLV Cal2 Positive calibrator 2 (lyophilized), 1 bottle for 1.0 mL:
Human serum, reactive for anti-HTLV antibodies.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Warning

- H317 May cause an allergic skin reaction.
- H412 Harmful to aquatic life with long lasting effects.

Prevention:

- P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
- P273 Avoid release to the environment.
- P280 Wear protective gloves.

Response:

- P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

All human material should be considered potentially infectious.

The calibrators (HTLV Cal1 and HTLV Cal2) have been prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV.

The testing methods used assays approved by the FDA or cleared in compliance with the European Directive 98/79/EC, Annex II, List A.

However, as no testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.^{13,14}

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents (M, R1, R2) in the kit are ready-for-use and are supplied in cobas e packs.

Calibrators:

Carefully dissolve the contents of 1 bottle by adding exactly 1.0 mL of distilled or deionized water and allow to stand closed for 15 minutes to reconstitute. Mix carefully, avoiding foam formation.

Transfer the reconstituted calibrators into the supplied empty labeled snap-cap bottles.

Unless the entire volume is necessary for calibration on the analyzer, transfer aliquots of the reconstituted calibrators into empty snap-cap bottles (CalSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots at 2-8 °C or -20 °C (± 5 °C) for later use.

Perform only one calibration procedure per aliquot.

All information required for correct operation is available via the cobas link.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the cobas e pack upright in order to ensure complete availability of the microparticles during automatic mixing prior to use.

| Stability of the cobas e pack: | |
|--------------------------------|----------------------------------|
| unopened at 2-8 °C | up to the stated expiration date |
| on the analyzers | 16 weeks |

| Stability of the calibrators: | |
|---------------------------------------|----------------------------------|
| lyophilized | up to the stated expiration date |
| reconstituted at 2-8 °C | 4 weeks |
| reconstituted at -20 °C (± 5 °C) | 16 weeks (freeze only once) |
| on the analyzers at 20-25 °C | use only once |

Store calibrators upright in order to prevent the calibrator solution from adhering to the snap-cap.

Specimen collection and preparation

Specimen collected from living patients, blood donors, or individual organ, tissue or cell donors may be used, including donor samples obtained while the donor's heart is still beating.

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, Na-heparin, K₂-EDTA, K₃-EDTA, ACD, CPD, CP2D, CPDA and Na-citrate plasma.

K₂-EDTA plasma tubes containing separating gel can be used.

Sampling devices containing liquid anticoagulants have a dilution effect resulting in lower cutoff-index (COI) values for individual patient specimens. In order to minimize dilution effects it is essential that respective sampling devices are filled completely according to manufacturer's instructions.

Criterion: Recovery of positive samples within ± 20 % of serum value. Absolute deviation of samples with COI values from 0.00-1.0 within ± 0.2 COI.

Stability:

For living patients and donor specimens obtained while the donor's heart is still beating: Stable for 7 days at 20-25 °C, 14 days at 2-8 °C, 3 months at -20 °C (± 5 °C). The samples may be frozen 5 times.

The sample types listed were tested with a selection of sample collection tubes or systems that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube/collection system manufacturer.

Centrifuge samples containing precipitates and thawed samples before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

The performance of the Elecsys HTLV-I/II assay has not been established with body fluids other than serum and plasma.

Materials provided

See "Reagents – working solutions" section for reagents.

- 2 x 6 bottle labels
- 2 x 2 empty labeled snap-cap bottles

Materials required (but not provided)

- [REF 07108133190](#), PreciControl HTLV, for 6 x 1.0 mL
- [REF 11776576322](#), CalSet Vials, 2 x 56 empty snap-cap bottles
- General laboratory equipment
- Distilled or deionized water
- cobas e analyzer

Additional materials for cobas e 402 and cobas e 801 analyzers:

- [REF 06908799190](#), ProCell II M, 2 x 2 L system solution
- [REF 04880293190](#), CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF 07485409001](#), Reservoir Cup, 8 cups to supply ProCell II M and CleanCell M
- [REF 06908853190](#), PreClean II M, 2 x 2 L wash solution
- [REF 05694302001](#), Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners
- [REF 07485425001](#), Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF 07485433001](#), PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF 11298500316](#), ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Place the cooled (stored at 2-8 °C) cobas e pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the cobas e pack.

Calibrators:

Place the reconstituted calibrators in the sample zone.
Read in all the information necessary for calibrating the assay.

Calibration

Traceability: No internationally accepted standard for HTLV-I/II exists. This method has been standardized against a Roche standard. The units have been selected arbitrarily.

Calibration frequency: Calibration must be performed once per reagent lot using HTLV Cal1, HTLV Cal2 and fresh reagent (i.e. not more than 24 hours since the cobas e pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
 - after 28 days when using the same cobas e pack on the analyzer
 - as required: e.g. quality control findings outside the defined limits
- Range for the electrochemiluminescence signals (counts) for the calibrators:

Negative calibrator (HTLV Cal1): 400-2000

Positive calibrator (HTLV Cal2): 15000-100000

Quality control

For quality control, use PreciControl HTLV.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per cobas e pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the cutoff based on the measurement of HTLV Cal1 and HTLV Cal2.

The result of a sample is given either as reactive or non-reactive as well as in the form of a cutoff index (signal sample/cutoff).

Interpretation of the results

| Numeric result | Result message | Interpretation/ further steps |
|--|---------------------|--|
| COI < 1.00 | Non-reactive | Negative for HTLV-I/II-specific antibodies, no further testing needed. |
| COI ≥ 1.00 | Reactive | All initially reactive samples should be retested in duplicate with the Elecsys HTLV-I/II assay. |
| Numeric result | Final result | Interpretation/ further steps |
| One or both of the duplicate retests have a COI ≥ 1.00 | Repeatedly reactive | The result must be confirmed according to recommended confirmatory algorithms. Confirmatory tests include Western Blot and HTLV PCR tests. |

| Numeric result | Final result | Interpretation/ further steps |
|---|--------------|---|
| Both of the duplicate retests have a COI < 1.00 | Non-reactive | Negative for HTLV-I/II-specific antibodies. |

Retesting of samples with an initial cutoff index ≥ 1.00 can be automatically performed (see section "cobas e flows").

cobas e flows

cobas e flows are procedures programmed into the system to enable a fully automated sequence of measurements and the calculation of assay combinations to perform decision algorithms.

A cobas e flow is available to perform a repetition of measurements in duplicate automatically for samples with an initial cutoff index ≥ 1.00 (short name HTLVR).

Both sub-results and the overall result message will be reported.

Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

Endogenous substances

| Compound | Concentration tested |
|--------------------|-------------------------------|
| Bilirubin | ≤ 1129 μmol/L or ≤ 66 mg/dL |
| Hemoglobin | ≤ 0.6 mmol/L or ≤ 1000 mg/dL |
| Intralipid | ≤ 2000 mg/dL |
| Biotin | ≤ 4912 nmol/L or ≤ 1200 ng/mL |
| Rheumatoid factors | ≤ 1200 IU/mL |
| IgG | ≤ 3.2 g/dL |
| IgA | ≤ 7 g/dL |
| IgM | ≤ 1 g/dL |

Criterion: Mean recovery of positive samples within ± 15%. Absolute deviation of samples with COI values from 0.0-1.0 within ± 0.2 COI.

Studies have been performed to assess the high-dose hook effect. Out of 1149 positive samples no false negative result was found. Occurrence of high-dose hook effect cannot be completely excluded.

Pharmaceutical substances

In vitro tests were performed on 17 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

A negative test result does not completely rule out the possibility of an infection with HTLV-I/II. Serum or plasma samples from the very early (pre-seroconversion) phase or the late phase of HTLV-I/II infection can occasionally yield negative findings.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

| cobas e 402 and cobas e 801 analyzers | | | | | |
|---------------------------------------|----------|-----------------------------|------|--------------------------------------|------|
| Sample | Mean COI | Repeatability ^{c)} | | Intermediate precision ^{d)} | |
| | | SD COI | CV % | SD COI | CV % |
| Human serum 1 | 0.100 | 0.00124 | 1.2 | 0.00172 | 1.7 |
| Human serum 2 | 0.968 | 0.0134 | 1.4 | 0.0226 | 2.3 |
| Human serum 3 | 0.906 | 0.0118 | 1.3 | 0.0201 | 2.2 |
| Human serum 4 | 1.12 | 0.0149 | 1.3 | 0.0267 | 2.4 |
| Human serum 5 | 5.88 | 0.0814 | 1.4 | 0.165 | 2.8 |
| Human serum 6 | 25.5 | 0.477 | 1.9 | 0.799 | 3.1 |
| PC ^{e)} HTLV 0 | 0.101 | 0.00199 | 2.0 | 0.00223 | 2.2 |
| PC HTLV 1 | 5.37 | 0.0960 | 1.8 | 0.135 | 2.5 |
| PC HTLV 2 | 2.79 | 0.0451 | 1.6 | 0.0733 | 2.6 |

c) Repeatability = within-run precision

d) Intermediate precision = between-run precision

e) PC = PreciControl

Analytical specificity

222 samples containing potentially interfering substances were tested with the Elecsys HTLV-I/II assay comprising specimens containing antibodies:

- against HIV, EBV, HSV-1/2, Rubella, HAV, HBV, HCV, E. coli
- from autoimmune diseases (e.g. ANA) and elevated titers of rheumatoid factor

No false reactive results were found with the Elecsys HTLV-I/II assay resulting in a specificity of 100%. Two samples were found repeatedly reactive with the Elecsys HTLV-I/II assay and were confirmed positive with HTLV immunoblot.

Clinical sensitivity

Of 1149 samples from HTLV-I/II infected patients of different geographical origin in different stages of the disease 1149 were found to be repeatedly reactive with the Elecsys HTLV-I/II assay. The sensitivity of the Elecsys HTLV-I/II assay in this study was 100%.

| Cohorts (by geographical origin) | N | Confirmed positive samples | Sensitivity % |
|----------------------------------|-----|----------------------------|---------------|
| Japan | 420 | 420 | 100 |
| South America | 134 | 134 | 100 |
| Caribbean | 97 | 97 | 100 |
| USA | 259 | 259 | 100 |
| Europe/Middle East | 236 | 236 | 100 |
| Africa | 3 | 3 | 100 |

| Cohorts (summarized by virus type) | N | Confirmed positive samples | Sensitivity % |
|------------------------------------|------|----------------------------|---------------|
| Total HTLV I | 926 | 926 | 100 |
| Total HTLV II | 200 | 200 | 100 |
| Total HTLV type unknown | 23 | 23 | 100 |
| Total | 1149 | 1149 | 100 |

Clinical specificity

A total of 13974 samples (diagnostic routine, pregnant women and blood donors) from 6 centers in Europe and Japan were tested with the Elecsys HTLV-I/II assay. The resulting specificity in the study was 99.95% in blood donors (n = 11575) and 99.83% in diagnostic routine including pregnant women (n = 2399). The 95% lower confidence limit was 99.89% in blood donors and 99.56% in diagnostic routine including pregnant women.

| Cohort | N | Confirmed positive samples | Indeterminate samples | Specificity ^{f)} % |
|---|------|----------------------------|-----------------------|-----------------------------|
| Blood donor serum | 9551 | 1 | 2 | 99.94 (99.86-99.98) |
| Blood donor EDTA plasma | 2024 | 0 | 1 | 100 (99.82-100) |
| Diagnostic routine (including pregnant women) | 2399 | 59 | 3 | 99.83 (99.56-99.95) |

f) 95% confidence interval, two-sided

References







- Conçalves DU, Proietti FA, Ribas JGR, et al. Epidemiology, Treatment and Prevention of Human T-Cell Leukemia Virus Type 1-Associated Diseases. *Clin Microbiol Rev* 2010;23(3):577-589.
- Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, et al. Global epidemiology of HTLV-I infection and associated diseases. *Oncogene* 2005;24(39):6058-6068.
- Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. *Lancet* 1999;353:1951-1958.
- Hall WW, Takahashi H, Liu C, et al. Multiple isolates and characteristics of human T-cell leukemia virus type II. *J Virol* 1992;66:2456-2463.
- Eiraku N, Novoa P, da Costa Ferreira M, et al. Identification and characterization of a new and distinct molecular subtype of human T-cell lymphotropic virus type 2. *J Virol* 1996;70:1481-1492.
- Vandamme AM, Salemi M, Van Brussel M, et al. African origin of human T-lymphotropic virus type 2 (HTLV-2) supported by a potential new HTLV-2d subtype in Congolese Bambuti Efe Pygmies. *Journal of virology* 1998;72(5):4327-4340.
- Schubach J. The Human Retroviruses Human Immunodeficiency Virus and Human T-Lymphotropic Virus. *Clinical Virology Manual* 2009. Washington, DC: American Society for Microbiology.
- Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. *Vox Sang* 1984;46:245-253.
- Cook LB, Elemans M, Rowan AG, et al. HTLV-1: Persistence and pathogenesis. *Virology* 2013;435:131-140.
- Murphy EL, Wang B, Sacher RA, et al. Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection. *Emerg Infect Dis* 2004;10:109-116.
- Zehender G, Colasante C, Santambrogio S, et al. Increased Risk of Developing Peripheral Neuropathy in Patients Coinfected With HIV-1 and HTLV-2. *JAIDS* 2002;31:440-447.
- Occupational Safety and Health Standards: Bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog. Roche.com for definition of symbols used):

| | |
|---|---|
|  | Contents of kit |
|  | Analyzers/Instruments on which reagents can be used |
|  | Reagent |
|  | Calibrator |
|  | Volume for reconstitution |
|  | Global Trade Item Number |

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of FreseniusKabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2021, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

